Shareholders to Vote on Massive 37.5x Increase in Authorized Shares
SILO sits 78% above its 52-week low of $3.315.
Summary
Silo Pharma has filed definitive proxy materials for its annual meeting, where shareholders will vote on a proposal to increase authorized common stock by 37.5 times, from 6.67 million to 250 million shares.
Key Events · Corporate Governance and Compliance · SILO
-
Shareholder Vote on Authorized Share Increase
Shareholders will vote on a proposal to increase authorized common stock from 6,666,667 to 250,000,000 shares at the Annual Meeting on August 14, 2026.
-
Potential for Significant Dilution
If approved, the 37.5-fold increase in authorized shares provides the company with substantial capacity for future equity financing or stock-based transactions, which could lead to significant dilution for current shareholders.
-
Follows Preliminary Proxy
This definitive filing confirms the proposals outlined in the preliminary proxy statement filed on June 18, 2026.
Analysis · SILO · Life Sciences
This definitive proxy statement confirms the company's proposal to increase its authorized common stock from 6.67 million to 250 million shares. This substantial increase, if approved, would provide the company with significant flexibility to issue new shares for future capital raises, acquisitions, or other corporate purposes, potentially leading to substantial dilution for existing shareholders. This follows the preliminary proxy filing on June 18, 2026.
At the time of this filing, SILO was trading at $5.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $3.32 to $15.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.